UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.) 1

Revolution Medicines, Inc.
(Name of Issuer)
Common Stock, \$0.0001 par value per share
(Title of Class of Securities)
76155X100
(CUSIP Number)
May 6, 2021
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
⊠ Rule 13d-1(c)
□ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act

(however, see the Notes).

1	NAME OF REPORT	TING PERSON	
	Biotechnology Value Fund, L.P.		
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR 1	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH	Ŭ	SIMILE VOINGIONER	
REPORTING		1,966,302	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		1,966,302	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,966,302		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	2.70/		
12	2.7% TYPE OF REPORT	ING PERSON	
12	TIFE OF REPORT	INO I LIGOIV	
	PN		

1	NAME OF DEDOR	TINC DEDCON		
1	NAME OF REPOR	NAME OF REPORTING PERSON		
	BVF I GP LLC			
2				
2	CHECK THE APP.	ROPRIATE BUX IF A MEMBER OF A GROUP	(a) ⊠ (b) □	
			(0) □	
3	SEC USE ONLY			
3	SEC USE ONLI			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	-	
-				
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING		1,966,302		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
	O	SHARED DISPOSITIVE POWER		
		1,966,302		
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,966,302			
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)		
	2.70/			
12	2.7%	FINC DEDCON		
12	TYPE OF REPORT	IIING PERSON		
	00			
	00			

1	NAME OF REPORTING PERSON			
	Providence William III I			
		Biotechnology Value Fund II, L.P.		
2	CHECK THE APPE	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠	
			(b) □	
3	SEC USE ONLY			
	SEC COE CIVEI			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	Delaware 5	SOLE VOTING POWER		
SHARES	5	SOLE VOTING FOWER		
BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING		1,477,295		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
	O	SHINED DISTOSTIVE FOWER		
		1,477,295		
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	4 455 005			
10	1,477,295	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П	
10	CHECK BOX IF II	TE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)		
- 10	2.0%	WING PERSON		
12	TYPE OF REPORT	ING PERSON		
	PN			
	PN			

1	NAME OF REPORT	TING PERSON	
	BVF II GP LLC		
2		COPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
2		OTRINIE BOX II A MILINDER OF A GROOT	(a) ⊡ (b) □
			. ,
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	- 1		
NUMBER OF	Delaware 5	SOLE VOTING POWER	
SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH REPORTING		1 477 205	
PERSON WITH	7	1,477,295 SOLE DISPOSITIVE POWER	
1210011 11111	,	SOLL DISTOSITIVE TOWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		1,477,295	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	1,477,295	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
10	CHECK BOX IF II	IE AGGREGATE AMOUNT IN NOW (9) EXCEODES CERTAIN STIARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	2.0%		
12	TYPE OF REPORT	ING PERSON	
	00		

1	NAME OF REPORT	TINC DEDCON		
1	NAME OF REPOR	NAME OF REPORTING PERSON		
	Biotechnology Value Trading Fund OS LP			
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠	
2	CHECK THE AFFI	COPRIATE BOX II. A MEMIDER OF A GROOF	(a) ⊠ (b) □	
			(0) 🗆	
3	SEC USE ONLY			
_				
4	CITIZENSHIP OR 1	PLACE OF ORGANIZATION		
	Cayman Island			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY EACH	6	SHARED VOTING POWER		
REPORTING		237,782		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
TERSON WITH	/	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		237,782		
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	237,782			
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	DEDCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
11	FERCENT OF CLA	22 KELKESENTED DI AMMOUNT IN KOW (3)		
	Less than 1%			
12	TYPE OF REPORT	ING PERSON		
	PN			

1	NAME OF REPORTING PERSON			
	DVF Deute our OC Ltd			
		BVF Partners OS Ltd.		
2	CHECK THE APPE	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □	
			(0) 🗆	
3	SEC USE ONLY		-	
	CITIZENCIUD OD	DI ACE OF ODG ANIZATION		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
	Cayman Islan	ds		
NUMBER OF	5	SOLE VOTING POWER		
SHARES		0.1		
BENEFICIALLY OWNED BY	6	0 shares SHARED VOTING POWER		
EACH	0	SHARED VOTING POWER		
REPORTING		237,782		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0.1		
	8	0 shares SHARED DISPOSITIVE POWER		
	O	SHARED DISPOSITIVE POWER		
		237,782		
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	227 702			
10	237,782 CHECK BOX IF THE	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П	
10	CILCIC DOZI II II	in the first through the first (a) in the first of the fi		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	Less than 1%			
12	TYPE OF REPORT	ING PERSON		
	CO			

1	NAME OF REPORT	TING PERSON	
	BVF GP HOLDINGS LLC		
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) 🗆
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		3,443,597	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0.1	
	8	0 shares SHARED DISPOSITIVE POWER	
	O .	SIMIKED DISTOSITIVE FOWER	
		3,443,597	
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	3,443,597		
10		IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	121GETT OF GERT	55 122 1252 112 BT 12400111 11 110 11 (5)	
	4.7%		
12	TYPE OF REPORTI	ING PERSON	
	00		

1	NAME OF REPORTING PERSON			
	DVE Data and L. D.			
		BVF Partners L.P.		
2	CHECK THE APPE	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □	
			(0) □	
3	SEC USE ONLY			
	CITIZENCIUD OD	DI ACE OF ODG ANIZATION		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY OWNED BY	6	0 shares SHARED VOTING POWER		
EACH	0	SHARED VOTING POWER		
REPORTING		3,757,049		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0.1		
	8	0 shares SHARED DISPOSITIVE POWER		
	0	SHARED DISPOSITIVE POWER		
		3,757,049		
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	2 757 040			
10	3,757,049	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П	
10	CILLON BOX II II	in the first through the first (a) in the first of the fi]	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	5.1%			
12	TYPE OF REPORT	ING PERSON		
	PN, IA			

1	NAME OF REPORT	TINC DEDSON		
1	NAME OF REPORT	TAINE OF REFORMING LEROOT		
	BVF Inc.			
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
			(b) 🗆	
3	SEC USE ONLY			
4	CITIZENCUID OD I	PLACE OF ORGANIZATION		
4	CITIZENSHIP OK I	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY	_	0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH REPORTING		3,757,049		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
	,	SOLL BIOLOGITIVE LOWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		0.777		
9	ACCDECATE AMO	3,757,049 OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
9	AGGREGATE AMO	JUNI BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	3,757,049			
10		IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	5.1%			
12	TYPE OF REPORT	NG PERSON		
12	TITE OF REPORTS	NO LEIGON		
	CO			

1	NAME OF REPORT	TINC DEDSON		
1	NAME OF REPOR	TAIME OF REFORTING LEROOT		
	Mark N. Lampert			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) 🗵	
2	CHECK THE ATT	OF MALE BOX IF A MEMBER OF A GROOT	(a) ⊠ (b) □	
			(6) \Box	
3	SEC USE ONLY			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
	United States			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY OWNED BY	6	0 shares SHARED VOTING POWER		
EACH	6	SHARED VOTING POWER		
REPORTING		3,757,049		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
1210011 ((1111	,	SOLE DISTOSITIVE TOWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		3,757,049		
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
10	3,757,049	IE A CODEC ATE A MOUNT IN DOM (O) EVOLUTES CEDITAIN CHADEC		
10	CHECK BOX IF II	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	1 LICEIVI OI GEN	55 121 125 21 111 15 511 11 11 11 (5)		
	5.1%			
12	TYPE OF REPORT	ING PERSON		
	IN			

Item 1(a). Name of Issuer:

Revolution Medicines, Inc., a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

700 Saginaw Drive Redwood City, CA 94063

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF I GP LLC ("BVF GP")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF II GP LLC ("BVF2 GP")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cavman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cavman Islands

Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Inc.

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common Stock, \$0.0001 par value per share (the "Shares").

Item 2(e). CUSIP Number:

76155X100

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment company registered under Section 8 of the Investment Company Act.
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	//	A church plan that is excluded from the definition of an investment company under Section $3(c)(14)$ of the Investment Company Act.
(j)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k)	//	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: $__$

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on May 17, 2021, (i) BVF beneficially owned 1,966,302 Shares, (ii) BVF2 beneficially owned 1,477,295 Shares and (iii) Trading Fund OS beneficially owned 237,782 Shares.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 1,966,302 Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,477,295 Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 237,782 Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 3,443,597 Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 3,757,049 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and a certain Partners managed account (the "Partners Managed Account"), including 75,670 Shares held in the Partners Managed Account.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 3,757,049 Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 3,757,049 Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on 73,442,594 Shares outstanding, which is the total number of Shares outstanding as of May 5, 2021 as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021.

As of the close of business on May 17, 2021, (i) BVF beneficially owned approximately 2.7% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.0% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 2.7% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 2.0% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 4.7% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 5.1% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF, BVF2, Trading Fund OS, the Partners Managed Account and BVF GPH.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: May 17, 2021

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC, its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF II GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert

President

/s/ Mark N. Lampert

MARK N. LAMPERT

17

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated May 17, 2021 with respect to the shares of Common Stock, \$0.0001 par value per share of Revolution Medicines, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated: May 17, 2021

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC, its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF II GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert President

/s/ Mark N. Lampert

MARK N. LAMPERT